On January 27, 2016, Tarveda Therapeutics, INC. has secured $38 million in Series C Financing co-led by new investor Novo A/S and existing investor NEA (New Enterprise Associates). Meanwhile, Tarveda also announced to change the former brand “Blend Therapeutic” to...
ShangPharma inks an Important Collaboration with Investment in Circle Pharma SAN FRANCISCO, Jan. 7, 2016 /PRNewswire/ — ChemPartner is delighted to announce the expansion of its extensive CRO service offerings into peptide chemistry. This comes along with a...
Chempartner will be attending the IBC’s Antibody Engineering & Therapeutics which is the largest and most trusted antibody engineering and therapeutics event in the industry in San Diego on December 7th-10th, 2015. Welcome to visit our booth and posters at this...
We are delighted to announce the completion of Phase 1 of our new South San Francisco Labs. Please join us for a reception to celebrate this important new initiative for ChemPartner. Our CEO, Michael Hui will be hosting this event and will be delighted to share our...
ShangPharma Biopharmaceutical Innovation and Development Forum is going to begin on October 19th , 2015, at Qidong Evergrande International Conference Center. As one of the serial activities of 2015 Qidong Science and Technology Festival, this Forum is co-hosted by...
Multi-omics approach to elucidate mechanism of cancer drug resistance SHANGHAI – [Apr. 13th, 2015] – ChemPartner, a leading science driven, technology based, high quality preclinical research partner for healthcare companies around the world, will unveil its...
New facility to help bring CRO to next level of scientific excellence. SHANGHAI – [Feb. 3rd, 2015] – ChemPartner, a leading science-driven, technology-based, high-quality preclinical research partner for healthcare companies around the world, recently expanded its...
